Loading
Premenstrual Dysphoric Disorder ( PMDD) / PMDD / Premenstrual Dysphoric Disorder · Observational Study
ClinicalTrials.gov · August 18, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a planned observational case–control study registered to explore inflammatory biomarkers and psychological factors in PMDD over two menstrual cycles. No results are yet available; the study has not begun recruiting. The record documents hypothesis-generating work linking immune activation to PMDD symptoms, with no effect estimates or comparisons.
Observational. Premenstrual Dysphoric Disorder, PMDD, Premenstrual Dysphoric Disorder ( PMDD), Premenstrual Dysphoric Disorder (PMDD); Female; age from 18 Years; to 42 Years; accepts healthy volunteers. Intervention: Control; Premenstrual Dysphoric Disorder (PMDD). Compared with: Healthy controls with mild or no premenstrual changes.. n = 120. 1 site: United Kingdom.
This is a planned observational case–control study registered to explore inflammatory biomarkers and psychological factors in PMDD over two menstrual cycles. No results are yet available; the study has not begun recruiting. The record documents hypothesis-generating work linking immune activation to PMDD symptoms, with no effect estimates or comparisons.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
This is a registry record for a planned observational study with no results posted; it describes enrollment and design only, representing early-phase descriptive work exploring biomarker associations in PMDD.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07771426). This is a study registration, not published results. Lead sponsor: King's College London. Recruitment status: NOT_YET_RECRUITING. Study type: OBSERVATIONAL. Enrollment: 120 participants (ESTIMATED). Conditions: Premenstrual Dysphoric Disorder, PMDD, Premenstrual Dysphoric Disorder ( PMDD), Premenstrual Dysphoric Disorder (PMDD). Primary outcome measures: Inflammatory Biomarkers (Comparing individuals with PMDD and controls) , From enrollment until study completion (approximately 3 months). Brief summary: Scientists have found that the immune system, the body's system dedicated to fighting infections, can be in a state of "hyperactivity" (i.e., more active than you would normally expect) in some people with depression and postnatal depression, despite the lack of any actual ongoing infection. This response is referred to as inflammation. This discovery has unveiled unique opportunities to identify new medications to help patients with this heightened inflammation who have also not been responding to their antidepressant medications. This study aims to explore how inflammation in the body may be linked to symptoms of Premenstrual Dysphoric Disorder (PMDD) across the menstrual cycle, and how thoughts, emotions, and behaviours also may change throughout the cycle. We are recruiting two groups of people: People with a clinical or provisional (suspected) diagnosis of PMDD, and healthy controls who experience mild/no premenstrual changes. Over a two-month period, participants will complete daily psychological assessments across two menstrual cycles and will come into King's College Hospital (KCH) twice during one menstrual cycle to provide blood samples to measure their inflammation. By comparing these groups, we hope to gain a better understanding of the biological and psychological factors involved in PMDD, with the long-term goal of improving treatment options.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.